DOCSLIB.ORG

Gastrointestinal Pathology Our Data Support the Notion That Optimized IHC Identification of CMV May Serve As a Gold Standard for the Diagnosis of CMV Colitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gastrointestinal Pathology Our Data Support the Notion That Optimized IHC Identification of CMV May Serve As a Gold Standard for the Diagnosis of CMV Colitis 144A ANNUAL MEETING ABSTRACTS As identification of CMV by histology/IHC rather than PCR has clinical implications, Gastrointestinal Pathology our data support the notion that optimized IHC identification of CMV may serve as a gold standard for the diagnosis of CMV colitis. 565 Unusual Immunohistochemistry Staining Patterns Encountered in Cancers Screened for Lynch Syndrome 567 Retrospective Study of Clinicopathologic Features and Patient Rocky Adams, Katherine Geiersbach, Sheryl Tripp, Wade Samowitz. University of Outcome of Primary Adenosquamous Carcinoma of the Esophagus Utah Health Sciences Center, ARUP Institute for Clinical & Experimental Pathology, Atin Agarwal, Dongfeng Tan, Susan Abraham, Melissa Taggart, Huamin Wang, Salt Lake City, UT; ARUP Institute for Clinical and Experimental Pathology, Salt Jeannelyn Estrella, Miao Zhang, Asif Rashid, Dipen Maru. Baylor College of Medicine, Lake City, UT. Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX. Background: Mismatch repair deficiency is associated with Lynch syndrome in a subset Background: Primary adenosquamous carcinoma (ASC) of the esophagus is an of colorectal and endometrial cancers, and universal screening is now recommended infrequent tumor with limited information on its biology and clinical behavior. for these tumors. Immunohistochemistry for four mismatch repair proteins (MLH1, Design: In a retrospective search of the institutional database (2001-2014) of MSH2, MSH6, and PMS2) is the most frequently used screening method. Although primary esophageal ASC, we identified 73 patients whose pathology was reviewed interpretation is usually straightforward for these stains, unusual patterns are encountered by a GI Pathologist. Forty-three of 73 patients with ASC diagnosed on pretreatment occasionally. Unusual staining patterns can lead to uncertainty about the possible biopsies were included in the study. Pretreatment clinical staging was confirmed by underlying gene defects. endoscopic ultrasound and/or CT/PET CT scans. The presence of Barrett’s esophagus Design: Retrospective review of 3,564 cases of cancer tested by immunohistochemistry was assessed either on esophagogastroduodenoscopy or pathology specimens. indicated that 727 (20%) were abnormal. The usual abnormal pattern was defined as loss Adenosquamous carcinoma was diagnosed based on presence of separate or admixed of both MLH1 and PMS2, loss of PMS2 alone, loss of both MSH2 and MSH6, or loss glandular and squamous component identified on H&E with or without mucicarmine of MSH6 alone in the entire tumor tested. Of the abnormal cases, a significant fraction or immunohistochemistry for keratin 5/6, p63, p40 and CDX-2. All patients with (93, almost 13%) showed unusual staining patterns. Unusual cases were stratified into advanced locoregional disease underwent chemoradiation with or without surgery. categories based on the staining pattern and histopathologic features. All stage IV patients underwent chemotherapy with or without palliative localized Results: The most common categories of unusual staining are indicated in Table 1. radiation. Esophagectomy specimens after preoperative chemoradiation were reviewed The patterns indicate different underlying mechanisms, both intrinsic to the biology of for presence of Barrett’s esophagus, amount of residual tumor and pathologic stage. the tumor (genetic heterogeneity or multiple gene defects) and extrinsic to the tumor Results: The patient population included 36 men and 7 women with an age range of 49- (chemoradiation and tissue preservation artifacts). 88 years. Tumor location was mid or distal esophagus in 25 (58%) and gastroesophageal Colorectal Endometrial Other junction in 18 (42%). Barrett’s esophagus was found in 13 (30%) patients. Two thirds Staining pattern Cancer Cancer Cancers Total (n=29) of patients presented with stage IV (n=28) or locally advanced unresectable (n = 57) (n = 31) (n = 5) disease (n=1). Six patients with locoregional disease demonstrated disease progression True heterogeneity (partial staining after preoperative chemoradiation. Five patients with locoregional disease had extensive of the tumor; absent staining in whole residual tumor in surgical resection specimens. Three patients with locoregional 22 20 2 44 regions of the tumor with retained disease demonstrated radiologic response to preoperative chemoradiation and were not internal control staining). operated due to high risk of operative morbidity. Only 3 of 41 (7%) patients survived Non-standard loss of staining indicating more than 3 years. 12* 3 1 16 a defect in more than one gene. Conclusions: Primary esophageal adenosquamous carcinoma has higher stage at presentation and poor response to preoperative chemoradiation. Unusual staining in the setting of prior 5 0 0 5 chemoradiation. 568 Prevalence and Clinical Significance of Microsatellite Instability Artifacts of tissue preservation and staining, preventing interpretation of 12 6 2 20 in Colorectal Cancers With Retained DNA Mismatch Repair Proteins By mismatch repair status in the tumor. Immunohistochemistry Agoston Agoston, Lynette Sholl, Neal Lindeman, Jason Hornick, Amitabh Srivastava. Unknown / other mechanisms. 7 2 0 9 Brigham & Women’s Hospital, Boston, MA. (*) 1 case showed two unusual staining patterns. Background: DNA mismatch repair (MMR) protein immunohistochemistry (IHC) is now used more often than microsatellite instability (MSI) testing by PCR to screen Conclusions: Multiple mechanisms can contribute to unusual staining patterns. These colorectal carcinomas (CRC) for Lynch Syndrome (LS). The rate of discordance reported unusual patterns are encountered infrequently overall but represent a significant in the literature between these two screening tests varies widely. The aim of our study proportion of abnormal cases (13% in our series). Better understanding of the was to determine the discordance rate between MMR IHC and MSI in a large series of mechanisms causing unusual immunohistochemistry staining patterns will enable CRC and to analyze its clinical significance. improved classification of tumors with mismatch repair deficiencies. Design: MMR IHC to screen for LS was performed in 2116 CRC between 1991-2014. MSI testing was also performed in 947/2116 cases, most commonly due to young age 566 Prognostic Implication of Optimized Detection of CMV By (<50 yrs) at CRC diagnosis. MMR IHC status was assessed using a four antibody panel Immunohistochemistry in CMV PCR-Positive Inflammatory Bowel Disease (MLH1, MSH2, MSH6, and PMS2) and scored as MMR deficient only when complete Patients loss of nuclear staining was seen in the tumor cells. Tumors were classified as MSI-high Kajsa Affolter, Jessica Johnson, John Valentine, Kathryn Peterson, Xinjian Chen. if >30% of tested loci showed instability. University School of Medicine, Salt Lake City, UT. Results: Mean age of the study group was 54 years and M:F ratio was 1:1.1. MMR Background: The significance of superimposed CMV infection in patients with IBD IHC was intact in 839/947 (89%) patients in whom both MMR IHC and MSI testing has been an issue of debate. Independent studies have reported a significantly higher was performed. Only 6/839 cases (0.7%) with intact MMR IHC were MSI-H, and incidence of colon CMV infection in patients with steroid-refractory IBD as compared represented 6% of the 106 MSI-H cases. Germline testing in two of these 6 patients (due to those with non-refractory disease, suggesting a contributory role of this virus in to young age, 35 and 46yrs, respectively, and strong family history of CRC) confirmed the disease process. Despite the relative high incidence, CMV was identified only in LS due to MLH1 point mutations in both cases. The results of genetic testing were not a small proportion (20 – 40%) of the steroid resistant patients. The reported lack of available in the remaining four patients but one had a family history suggestive of LS. colon CMV infection in the majority of these patients raises the question whether CMV Conversely, 8/841 (0.95%) patients with either microsatellite stable (MSS) tumors infection is truly not associated with the patients or the negative result is due to the low (n=738) or tumors with low level MSI (MSI-L) (n=103) showed abnormal results by sensitivity of the examination. MMR IHC . 3/8 discordant cases were MSI-L and two of these three were LS patients Design: To address this question, we identified 26 IBD patients whose intestinal biopsies (both MSH6 mutations) . The third MSI-L patient had loss of MLH1/PMS2 on IHC or resection specimens were CMV PCR positive, and performed CMV IHC on all the but no genetic testing was available and family history was not suggestive of LS. Of tissue blocks that were initially found to be CMV negative per H&E. the 5/8 discordant MSS cases (3 with MSH2/MSH6 loss, 2 with only MSH6 loss), 3 Results: Re-examination of 153 tissue blocks derived from 37 separate colonoscopy were negative for LS by genetic testing, and 2 did not have genetic testing and did not and colectomy specimens from 26 IBD patients (representing 28 separate clinical CMV have a family history suggestive of LS. infections) identified additional CMV inclusions in patients whom were diagnosed CMV Conclusions: Discordance between intact MMR IHC and MSI testing is rare (0.7%) negative by H&E or IHC performed only on selected blocks in the initial examination. in CRC, and there was no clear trend favoring either method. Performing MSI testing However, despite the enhanced sensitivity, IHC
Load more

Recommended publications
  • A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia
    Protocol 01-2017: RFA for Anal Intraepithelial Neoplasia A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using The BARRX™ Anorectal Wand (Clinical Protocol 01-2017) AUGUST 31, 2017 Page 1 of 40 Protocol 01-2017: RFA for Anal Intraepithelial Neoplasia PROTOCOL SIGNATURE PAGE I, , Principal Investigator at site , agree to conduct and follow this protocol: PROTOCOL 01-2017: A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for Anal Intraepithelial Neoplasia using the Barrx™ Anorectal Wand as written according to FDA guidelines. I understand that no deviations from the above protocol may be made without written permission from the Protocol Chair(s). _________________________________ _____________________ Signature Date (mm/dd/yyyy) Page 2 of 40 Protocol 01-2017: RFA for Anal Intraepithelial Neoplasia P ROT O COL S U M M ARY Title A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for Anal Intraepithelial Neoplasia using the Barrx™ Anorectal Wand Design Multi-center prospective trial involving up to 70 subjects Subject Population HIV-positive and HIV-negative subjects with intra-anal intraepithelial neoplasia (AIN) containing at least one high- grade squamous intraepithelial lesions (HSIL) involving the squamocolumnar junction (SCJ). Objective Assess the safety, and efficacy of circumferential radiofrequency ablation (RFA) to the anal canal using the FDA cleared Barrx™ Anorectal Wand to eradicate anal
    [Show full text]
  • Detail Report
    Supplemental Update Report CR Number: 2012319113 Implementation Date: 16-Jan-19 Related CR: 2012319113 MedDRA Change Requested Add a new SMQ Final Disposition Final Placement Code # Proposed SMQ Infusion related reactions Rejected After Suspension MSSO The proposal to add a new SMQ Infusion related reactions is not approved after suspension. The ICH Advisory Panel did approve this SMQ topic to go into the development phase and it Comment: underwent testing in three databases (two regulatory authorities and one company). However, there were numerous challenges encountered in testing and the consensus decision of the CIOMS SMQ Implementation Working Group was that the topic could not be developed to go into production as an SMQ. Most notably, in contrast to other SMQs, this query could not be tested using negative control compounds because it was not possible to identify suitable compounds administered via infusion that were not associated with some type of reaction. In addition, there is no internationally agreed definition of an infusion related reaction and the range of potential reactions associated with the large variety of compounds given by infusion is very broad and heterogenous. Testing was conducted on a set of around 500 terms, the majority of which was already included in Anaphylactic reaction (SMQ), Angioedema (SMQ), and Hypersensitivity (SMQ). It proved difficult to identify potential cases of infusion related reactions in post-marketing databases where the temporal relationship of the event to the infusion is typically not available. In clinical trial databases where this information is more easily available, users are encouraged to provide more specificity about the event, e.g., by reporting “Anaphylactic reaction” when it is known that this event is temporally associated with the infusion.
    [Show full text]
  • Perineural Invasion As a Risk Factor for Locoregional Recurrence of Invasive Breast Cancer Priyanka Narayan1, Jessica Flynn2, Zhigang Zhang2, Erin F
    www.nature.com/scientificreports OPEN Perineural invasion as a risk factor for locoregional recurrence of invasive breast cancer Priyanka Narayan1, Jessica Flynn2, Zhigang Zhang2, Erin F. Gillespie3, Boris Mueller3, Amy J. Xu3, John Cuaron3, Beryl McCormick3, Atif J. Khan3, Oren Cahlon3, Simon N. Powell3, Hannah Wen4 & Lior Z. Braunstein3* Perineural invasion (PNI) is a pathologic fnding observed across a spectrum of solid tumors, typically with adverse prognostic implications. Little is known about how the presence of PNI infuences locoregional recurrence (LRR) among breast cancers. We evaluated the association between PNI and LRR among an unselected, broadly representative cohort of breast cancer patients, and among a propensity-score matched cohort. We ascertained breast cancer patients seen at our institution from 2008 to 2019 for whom PNI status and salient clinicopathologic features were available. Fine-Gray regression models were constructed to evaluate the association between PNI and LRR, accounting for age, tumor size, nodal involvement, estrogen receptor (ER), progesterone receptor (PR), HER2 status, histologic tumor grade, presence of lymphovascular invasion (LVI), and receipt of chemotherapy and/or radiation. Analyses were then refned by comparing PNI-positive patients to a PNI-negative cohort defned by propensity score matching. Among 8864 invasive breast cancers, 1384 (15.6%) were noted to harbor PNI. At a median follow-up of 6.3 years, 428 locoregional recurrence events were observed yielding a 7-year LRR of 7.1% (95% CI 5.5–9.1) for those with PNI and 4.7% (95% CI 4.2–5.3; p = 0.01) for those without. On univariate analysis throughout the entire cohort, presence of PNI was signifcantly associated with an increased risk of LRR (HR 1.39, 95% CI 1.08– 1.78, p < 0.01).
    [Show full text]
  • Infectious Gastroenteritis Generalised Anxiety Disorder HIV Smoking Associated Cancers
    BEST PRACTICE 25 DECEMBER 2009 Infectious gastroenteritis Generalised anxiety disorder HIV bpac nz Smoking associated cancers better medicin e Editorial Team Tony Fraser Professor Murray Tilyard We would like to acknowledge the following people for Clinical Advisory Group their guidance and expertise in developing this edition: Michele Cray Dr Shaun Costello, Dunedin Serena Curtis-Lemuelu Dr Edward Coughlan, Christchurch Dr Rosemary Ikram Professor Tony Dowell, Wellington Dr Cam Kyle Dr Rosemary Ikram, Christchurch Dr Chris Leathart Mr William Pearce, Christchurch Dr Lynn McBain Dr Alan Pithie, Christchurch Adam McRae Dr Gabrielle Ruben, Wellington Janet Maloney-Moni Assoc. Professor Mark Thomas, Auckland Dr Peter Moodie Dr Robyn Toomath, Wellington Associate Professor Jim Reid Dr Neil Whittaker, GP Reviewer, Nelson Associate Professor David Reith Assoc. Professor Michael Williams, Dunedin Professor Murray Tilyard Programme Development Team Rachael Clarke Peter Ellison Best Practice Journal (BPJ) Rebecca Harris Julie Knight ISSN 1177-5645 Noni Richards BPJ, Issue 25, December 2009 Dr Tom Swire Dr AnneMarie Tangney nz Dr Sharyn Willis BPJ is published and owned by bpac Ltd Dave Woods Level 8, 10 George Street, Dunedin, New Zealand. Report Development Team Bpacnz Ltd is an independent organisation that promotes health Justine Broadley care interventions which meet patients’ needs and are evidence Todd Gillies based, cost effective and suitable for the New Zealand context. Lana Johnson We develop and distribute evidence based resources which describe, facilitate and help overcome the barriers to best Web practice. Gordon Smith Bpacnz Ltd is currently funded through contracts with PHARMAC Design and DHBNZ. Michael Crawford Bpacnz Ltd has five shareholders: Procare Health, South Link Management and Administration Health, IPAC, the University of Otago and Pegasus Health.
    [Show full text]
  • Pathology of Anal Cancer
    Pathology of Anal Cancer a b Paulo M. Hoff, MD, PhD , Renata Coudry, MD, PhD , a, Camila Motta Venchiarutti Moniz, MD * KEYWORDS Anal cancer Anal squamous intraepithelial neoplasia Squamous cell carcinoma Human papilloma virus (HPV) Molecular KEY POINTS Anal cancer is an uncommon tumor, squamous cell carcinoma (SCC) being the most frequent histology corresponding to 80% of all cases. Human papilloma virus (HPV) infection plays a key role in anal cancer development, en- coding at least three oncoproteins with stimulatory properties. SCC expresses CK5/6, CK 13/19, and p63. P16 is a surrogate marker for the presence of HPV genome in tumor cells. INTRODUCTION Anal cancer accounts for approximately 2.4% of gastrointestinal malignancies.1 Although anal cancer is a rare tumor, its frequency is increasing, especially in high- risk groups.2 Tumors in this location are generally classified as anal canal or anal margin. Squamous cell carcinoma (SCC) is the predominant type of tumor and shares many features with cervical cancer. Oncogenic human papilloma virus (HPV) infection plays a major role in both tumors.3 HIV infection is associated with a higher frequency of HPV-associated premalignant lesions and invasive tumors.4 Normal Anatomy of the Anus The anal canal is the terminal part of the large intestine and is slightly longer in male than in female patients. It measures approximately 4 cm and extends from the rectal ampulla (pelvic floor level) to the anal verge, which is defined as the outer open- ing of the gastrointestinal tract. The anal verge is at the level of the squamous- mucocutaneous junction with the perianal skin.5,6 The authors have nothing to disclose.
    [Show full text]
  • HPV, Anal Dysplasia and Anal Cancer
    HPV, anal dysplasia FACT and anal cancer SHEET Published 2016 Summary Anal cancer typically develops over a period of years, beginning with a precancerous condition called anal dysplasia. CONTACT US Anal dysplasia occurs when clusters of abnormal cells form by telephone lesions in the mucosa lining of the anal canal (between the 1-800-263-1638 anus and the rectum). The lesions typically form inside the anal 416-203-7122 canal or just outside the anal opening. by fax 416-203-8284 Although there are over 100 different types of the human papillomavirus (HPV), anal dysplasia is usually caused by certain by e-mail strains of HPV which can be transmitted sexually. HPV can shut info@catie.ca off the proteins that help prevent dysplasia and cancer cells from developing, therefore leading to HPV-associated diseases by mail such as anal dysplasia. 555 Richmond Street West Suite 505, Box 1104 It is difficult to screen for anal dysplasia since the lesions are Toronto ON M5V 3B1 not detectable by routine examinations. As a result, anal dysplasia is often not detected until it has developed into anal cancer, which can be difficult to treat depending on the severity. Specific screening tests can detect dysplasia or precancerous changes. If these precancers are treated, anal cancer may be prevented. Anal cancer is usually treated with radiation and chemotherapy or with surgery. Although anal dysplasia may be treated successfully, individuals with HIV are at increased risk of it recurring and may need to be monitored closely by a trained physician. Consistent condom use reduces, but does not eliminate, the risk of transmitting HPV.
    [Show full text]
  • Needle Biopsy and Radical Prostatectomy Specimens David J Grignon
    Modern Pathology (2018) 31, S96–S109 S96 © 2018 USCAP, Inc All rights reserved 0893-3952/18 $32.00 Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens David J Grignon Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, IUH Pathology Laboratory, Indianapolis, IN, USA Prostatic adenocarcinoma remains the most common cancer affecting men. A substantial majority of patients have the diagnosis made on thin needle biopsies, most often in the absence of a palpable abnormality. Treatment choices ranging from surveillance to radical prostatectomy or radiation therapy are largely driven by the pathologic findings in the biopsy specimen. The first part of this review focuses on important morphologic parameters in needle biopsy specimens that are not covered in the accompanying articles. This includes tumor quantification as well as other parameters such a extraprostatic extension, seminal vesicle invasion, perineural invasion, and lymphovascular invasion. For those men who undergo radical prostatectomy, pathologic stage and other parameters are critical in prognostication and in determining the appropriateness of adjuvant therapy. Staging parameters, including extraprostatic extension, seminal vesicle invasion, and lymph node status are discussed here. Surgical margin status is also an important parameter and definitions and reporting of this feature are detailed. Throughout the article the current reporting guidelines published by the College of American Pathologists and the International Collaboration on Cancer Reporting are highlighted. Modern Pathology (2018) 31, S96–S109; doi:10.1038/modpathol.2017.167 The morphologic aspects of prostatic adenocarcinoma hormonal therapy.4,5 For needle biopsy specimens the have a critical role in the management and prognos- data described below are largely based on standard tication of patients with prostatic adenocarcinoma.
    [Show full text]
  • Perineural Invasion in Oral Squamous Cell Carcinoma: a Discussion of Significance and Review of the Literature ⇑ Nada O
    Oral Oncology 47 (2011) 1005–1010 Contents lists available at SciVerse ScienceDirect Oral Oncology journal homepage: www.elsevier.com/locate/oraloncology Review Perineural invasion in oral squamous cell carcinoma: A discussion of significance and review of the literature ⇑ Nada O. Binmadi a,b, John R. Basile a,c, a Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, 650 West Baltimore Street, 7-North, Baltimore, MD 21201, USA b Department of Oral Basic & Clinical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia c Marlene and Stuart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA article info summary Article history: Perineural invasion (PNI) is a tropism of tumor cells for nerve bundles in the surrounding stroma. It is a Received 20 May 2011 form of tumor spread exhibited by neurotropic malignancies that correlates with aggressive behavior, Received in revised form 27 July 2011 disease recurrence and increased morbidity and mortality. Oral squamous cell carcinoma (OSCC) is a neu- Accepted 1 August 2011 rotropic malignancy that traditionally has been difficult to treat and manage. Evidence suggests that Available online 23 August 2011 demonstration of PNI in OSCC should impact adjuvant treatment decisions and surgical management of this disease. Despite its importance as a prognostic indicator, experimental studies to explore the Keywords: molecular mechanisms responsible for PNI are limited. The aim of this review is to discuss the difficulties Oral squamous cell carcinoma in evaluating for PNI, review the literature regarding the relationship of PNI with patient outcomes in Perineural invasion Metastasis OSCC, and summarize the recent studies describing the molecular agents associated with this patholog- Neurotropic carcinoma ical phenomenon.
    [Show full text]
  • Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: a Retrospective Cohort Study
    pathogens Article Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: A Retrospective Cohort Study Javier Corral 1,2,3,*, David Parés 1,2,3, Francesc García-Cuyás 1,2, Boris Revollo 2,4, Ana Chamorro 2,4, Carla Lecumberri 2,5 , Antoni Tarrats 2,5, Eva Castella 6, Marta Piñol 1,2, Bonaventura Clotet 2,3,7, Sebastià Videla 2,8,*,† and Guillem Sirera 2,4,† 1 Department of General Surgery, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; dapares@gmail.com (D.P.); 31557fgc@gmail.com (F.G.-C.); 19483mpp@gmail.com (M.P.) 2 Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; brevollo@flsida.org (B.R.); achamorro@flsida.org (A.C.); carlalecu@gmail.com (C.L.); atarrats.germanstrias@gencat.cat (A.T.); BClotet@irsicaixa.es (B.C.); gsirera@flsida.org (G.S.) 3 School of Medicine, Universitat Autónoma de Barcelona (UAB), Edifici M, Av. de Can Domènech, Bellaterra, 08193 Barcelona, Spain 4 HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain 5 Department of Obstetrics and Gynaecology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain 6 Department of Pathology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, Citation: Corral, J.; Parés, D.; 08916 Barcelona, Spain; castella61@gmail.com García-Cuyás, F.; Revollo, B.; 7 Retrovirology Laboratory IrsiCaixa Foundation, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain Chamorro, A.; Lecumberri, C.; Tarrats, 8 Department of Clinical Pharmacology, Bellvitge University Hospital/IDIBELL/University of Barcelona, A.; Castella, E.; Piñol, M.; Clotet, B.; Hospitalet de Llobregat, Gran Via de les Corts Catalanes 199–203, 08907 Barcelona, Spain et al.
    [Show full text]
  • Use of Human Papillomavirus Ge
    Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients Clarisse Dupin, Laurent Siproudhis, Sébastien Hénno, Sophie Minjolle, Cédric Arvieux, Pierre Tattevin To cite this version: Clarisse Dupin, Laurent Siproudhis, Sébastien Hénno, Sophie Minjolle, Cédric Arvieux, et al.. Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients. Digestive and Liver Disease, WB Saunders, 2015, 47(5), pp.423-428. 10.1016/j.dld.2015.01.150. hal-01147275 HAL Id: hal-01147275 https://hal-univ-rennes1.archives-ouvertes.fr/hal-01147275 Submitted on 22 Oct 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients Clarisse Dupin,a,b, Laurent Siproudhis,b,c Sébastien Henno,b,d Sophie Minjolle,a,b Cédric Arvieux,b,e Pierre Tattevinb,e Department of Virology, Pontchaillou
    [Show full text]
  • Christopher Mathews, M.D. UCSD Owen Clinic April 13, 2017 Clinical Case
    Screening for Anal Cancer and Precursors in HIV Patients Christopher Mathews, M.D. UCSD Owen Clinic April 13, 2017 Clinical Case • 50 year old asymptomatic physician with HIV infection presented for routine care in May 1999 • CD4=350, HIV viral load 35,000 • Physical exam normal except for 3 cm irregular hard anal mass • Biopsy: invasive squamous cell carcinoma 2 Clinical Case -2 • Resection had positive margins • He was treated with radiotherapy and mitomycin C + 5FU • Severe disabling radiation proctitis • Biopsy at end of treatment showed residual tumor • Abdominal perineal resection in 11/99 • Small bowel obstructionileocolic anastasmosis (3/00) • Bilateral hydronephrosis and renal failure • Declined intervention • Viral load <50 prior to withdrawal of therapy 3 Learning Objectives • Review current HPV vaccination guidelines for HIV-infected adults • Review guidelines related to screening for anal cancer and its precursors in HIV-infected patients • Review the evidence base to support screening • Describe screening options and procedures as related to screening goals and screening procedure expertise 4 Polling question 1 • Which groups of HIV-infected patients should be routinely offered HPV vaccination? (select the one best answer) – All HIV-infected adults who have not yet been vaccinated – All HIV-infected males and females ≤ 21 years of age – All HIV-infected males and females ≤ 26 years of age – The HPV vaccines are unlikely to be immunogenic and shouldn’t be given to HIV-infected patients – The HPV vaccines are live attenuated vaccines and shouldn’t be administered to HIV-infected patients 5 Polling question 2 • According to 2016 CDC guidelines, how many HPV vaccinations are recommended to complete the series for HIV-infected patients? – 1 – 2 – 3 6 HPV VACCINATION UPDATE 7 HPV Vaccination Recommendations: 2016 update 1.Meites E, et al.
    [Show full text]
  • STI / HPV / Cancer
    HIV, cancer, HPV & STI’s S. De Wit St Pierre University hospital Brussels HIV and cancer • AIDS-defining malignancies: – Kaposi’s sarcoma HHV8 – Non Hodgkin lymphoma 1985 EBV – Cervical cancer 1993 HPV • Non AIDS-defining malignancies (NADM) is increasing • Linked with virus HPV (Anal), HBV and HCV (Liver), EBV (HL) • Linked with previous immunodeficiency and other factors Background • Before introduction of HAART, ADCs common, including Kaposi’s sarcoma, NHL, and invasive cervical carcinoma • Rate of ADCs significantly increased from early to late pre-HAART era and then significantly decreased following introduction of HAART • Rates of nADCs stable during pre-HAART eras and then significantly increased following introduction of HAART Crum-Cianflone N, et al. AIDS. 2009;23:41-50. AIDS-Defining Cancer SIR = Standardised Incidence Ratio = Nb cases of cancer in the HIV population Expected nb of cases in the general population, calculated with local cancer registry incidence Cancer Incidence in AIDS Patients Cancer type No. cases SIR 95% CI AIDS-defining cancers Kaposi sarcoma 3136 5321 5137 - 5511 • Study of cancer risk in AIDS Non-Hodgkin 3345 32 31 - 33 patients from 1980-2006 lymphoma (N=372,364) Cervical cancer 101 5.6 5.5 - 6.8 • Predominantly male (79%), Non-AIDS-defining cancers non-hispanic black (42%), MSM (42%) Anal cancer 219 27 24 - 31 • Median age of 36 years Liver cancer 86 3.7 3.0 - 4.6 at the onset of AIDS Lung cancer 531 3.0 2.8 - 3.3 Hodgkin lymphoma 184 9.1 7.7 - 11 All non-AIDS 2155 1.7 1.5 - 1.8 related cancers SIR=Standardized Incidence Ratios Simard E, et al.
    [Show full text]